Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helix BioPharma, a Canada-based biopharmaceutical company, has reported a loss of C$4.25 million, or C$0.08 per share, for the second quarter ended January 31, 2009, compared to a loss of C$1.53 million, or C$0.04 per share, for the second quarter ended January 31, 2008.
Subscribe to our email newsletter
The company recorded a loss of C$6.57 million, or C$0.13 per share, for the six-month period ended January 31, 2009, compared to a loss of C$3.17 million, or C$0.08 per share, for the same period of 2008.
For the three-month period ended January 31, 2009, the company reported revenues of C$863,000, an increase of 9.1%, compared to C$791,000 for the same period of 2008. Total revenues, for the six-month period ended January 31, 2009, totaled C$1.98 million, an increase of 18.3%, compared to C$1.68 million for the corresponding period of 2008.